Surrozen, Inc. (SRZN)
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration.
It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts.
The company was founded in 2016 and is headquartered in South San Francisco, California.
171 Oyster Point Boulevard
South San Francisco, CA 94080
|Phone||650 489 9000|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Craig C. Parker M.B.A.||Chief Executive Officer, President and Director|
|Charles Williams||Chief Financial Officer|
|Dr. Wen-Chen Yeh M.D., Ph.D.||Chief Scientific Officer|
|Dr. K. Christopher Garcia||Co-Founder and Member of Scientific Advisor|
|Dr. Roeland Nusse Ph.D.||Co-Founder and Member of Scientific Advisor|
|Dr. Calvin Kuo||Co-Founder and Member of Scientific Advisor|
|Dr. Johannes Carolus Clevers M.D., Ph.D.||Co-Founder and Member of Scientific Advisor|
|Sheela Mohan-Peterson||Vice President of Legal|
|Reza Afkhami M.B.A.||Vice President of Corporate Development and Strategy|
|Elizabeth Nguyen||Head of Human Resources and Vice President|
Latest SEC Filings
|Nov 16, 2021||424B3||Prospectus [Rule 424(b)(3)]|
|Nov 15, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Nov 15, 2021||8-K||Current report|
|Nov 9, 2021||424B3||Prospectus [Rule 424(b)(3)]|
|Nov 10, 2021||EFFECT||Notice of Effectiveness|
|Nov 8, 2021||S-1/A||General form for registration of securities under the Securities Act of 1933|
|Nov 8, 2021||S-8||Securities to be offered to employees in employee benefit plans|
|Sep 29, 2021||SC 13D/A||General statement of acquisition of beneficial ownership|
|Sep 13, 2021||S-1||General form for registration of securities under the Securities Act of 1933|
|Aug 23, 2021||SC 13D||General statement of acquisition of beneficial ownership|
|View All SEC Filings|